pidemiologic observations have reported an association between statin therapy and decreased risk of dementia and Alzheimer's disease (AD). The mechanisms are not fully elucidated but may include effects on vascular risk factors or direct effects on amyloid metabolism itself. However, these observations of protective effects have not been borne out in two randomised controlled trials with dementia prevention as an outcome. 1 The association between statin therapy and dementia/AD risk may vary by age: in the Canadian Study of Health and Aging (CSHA), the use of statins or another lipid-lowering agent was associated with lower OR for AD only in participants <80 years (OR, 0.26; 95% CI, 0.09 to 0.72) but not in participants >80 years.
This fi nding led the authors to re-examine these questions in a rigorously studied cohort of older persons (Adult Changes in Thought) who are members of a health maintenance organisation (Group Health Cooperative, GHC). Three thousand and ninety-nine GHC members >65 years of age were recruited in two cohorts and followed for a mean of 6.1 years. Statin use was associated with lower odds of AD in participants <80 years but not in participants >80 years.
Together with the CSHA results, these results suggest a possible protective effect of statins against AD in persons <80 years. The results are plausible mechanistically, since there is increasing evidence that the preclinical stage of AD starts years before clinical symptoms and that AD neurotoxic mechanisms are stage-specifi c. Thus it is reasonable that the protective effect of a medication might only be observed when started as early as possible in the preclinical stage of AD. The time may be upon us to undertake a prevention trial of statins in 'young-old' participants, very possibly with a short-term biomarker outcome as well as longterm dementia outcomes. One cannot recommend the use of statins clinically for AD prevention at this time, without the results of a randomised controlled trial, since epidemiologic observations in this area have often not been borne out by trials (as in the case of estrogens). 
Paul B Rosenberg

METHODS
Design:
Prospective cohort study. Follow-up period: Average of 6.1 years.
MAIN RESULTS
Of the 3392 enrolled participants, 3099 had at least one follow-up examination and were included in the analysis. 711 had taken statins for an average of 5.4 (±3.6) years. Self-reported comorbid vascular conditions, cigarette smoking, higher serum total cholesterol, lower high-density lipoprotein cholesterol and higher body mass index were more common in those exposed to statins. During follow-up, 263 participants developed probable AD; mean age of onset was 82. 
CONCLUSIONS
Statin use in people aged 65-80 years appears to reduce the risk of AD; however, this association between statin use and AD was not observed in statin users who were older than 80 at study entry.
